Eriksen JG - Search Results

1

Analysis of CT-verified loco-regional recurrences after definitive IMRT for HNSCC using site of origin estimation methods.

Zukauskaite R, Hansen CR, Brink C, Johansen J, Asmussen JT, Grau C, Overgaard J, Eriksen JG. Zukauskaite R, et al. Among authors: eriksen jg. Acta Oncol. 2017 Nov;56(11):1554-1561. doi: 10.1080/0284186X.2017.1346384. Epub 2017 Aug 22. Acta Oncol. 2017. PMID: 28826293

2

Esthesioneuroblastoma--what is the optimal treatment?

Eriksen JG, Bastholt L, Krogdahl AS, Hansen O, Joergensen KE. Eriksen JG, et al. Acta Oncol. 2000;39(2):231-5. doi: 10.1080/028418600430833. Acta Oncol. 2000. PMID: 10859017

3

Importance of overall treatment time for the response to radiotherapy in patients with squamous cell carcinoma of the head and neck.

Overgaard J, Alsner J, Eriksen J, Horsman MR, Grau C. Overgaard J, et al. Rays. 2000 Jul-Sep;25(3):313-9. Rays. 2000. PMID: 11367896 Review.

4

The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck.

Eriksen JG, Steiniche T, Askaa J, Alsner J, Overgaard J. Eriksen JG, et al. Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):561-6. doi: 10.1016/j.ijrobp.2003.09.043. Int J Radiat Oncol Biol Phys. 2004. PMID: 14751528

5

Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas.

Eriksen JG, Buffa FM, Alsner J, Steiniche T, Bentzen SM, Overgaard J. Eriksen JG, et al. Radiother Oncol. 2004 Sep;72(3):275-82. doi: 10.1016/j.radonc.2004.07.014. Radiother Oncol. 2004. PMID: 15450725 Clinical Trial.

6

Expression of integrins and E-cadherin in squamous cell carcinomas of the head and neck.

Eriksen JG, Steiniche T, Søgaard H, Overgaard J. Eriksen JG, et al. APMIS. 2004 Sep;112(9):560-8. doi: 10.1111/j.1600-0463.2004.apm1120902.x. APMIS. 2004. PMID: 15601304

7

The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study.

Eriksen JG, Steiniche T, Overgaard J; Danish Head and Neck Cancer study group (DAHANCA). Eriksen JG, et al. Radiother Oncol. 2005 Feb;74(2):93-100. doi: 10.1016/j.radonc.2004.12.018. Radiother Oncol. 2005. PMID: 15816106 Clinical Trial.

8

The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma.

Eriksen JG, Steiniche T, Overgaard J; Danish Head and Neck Cancer study group (DAHANCA). Eriksen JG, et al. Acta Oncol. 2005;44(1):50-8. doi: 10.1080/02841860510007396. Acta Oncol. 2005. PMID: 15848906 Clinical Trial.

9

The possible role of TP53 mutation status in the treatment of squamous cell carcinomas of the head and neck (HNSCC) with radiotherapy with different overall treatment times.

Eriksen JG, Alsner J, Steiniche T, Overgaard J. Eriksen JG, et al. Radiother Oncol. 2005 Aug;76(2):135-42. doi: 10.1016/j.radonc.2005.05.004. Radiother Oncol. 2005. PMID: 16024113

10

Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial.

Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR; Danish Head and Neck Cancer Study Group. Overgaard J, et al. Among authors: eriksen jg. Lancet Oncol. 2005 Oct;6(10):757-64. doi: 10.1016/S1470-2045(05)70292-8. Epub 2005 Aug 27. Lancet Oncol. 2005. PMID: 16198981 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

142 results

Search Page

Filters